Significant Efficacy of Apatinib in a Patient With Hepatocellular Carcinoma Lung Metastases After Liver Transplantation: A Case Report

被引：1

作者：

Yu, Z. ^{[1
,2
]}

Liu, W. ^{[3
]}

Deng, Y. ^{[1
,2
]}

Yao, J. ^{[1
,2
]}

Tang, H. ^{[1
,2
]}

Li, H. ^{[1
,2
]}

Yang, Y. ^{[1
,2
,3
]}

Wang, G. ^{[1
,2
]}

Chen, G. ^{[3
]}

机构：

[1] Sun Yat Sen Univ, Dept Hepat Surg, Organ Transplantat Res Ctr Guangdong Prov, Guangzhou, Guangdong, Peoples R China

[2] Sun Yat Sen Univ, Liver Transplantat Ctr, Organ Transplantat Res Ctr Guangdong Prov, Affiliated Hosp 3,Organ Transplantat Inst, Guangzhou, Guangdong, Peoples R China

[3] Sun Yat Sen Univ, Affiliated Hosp 3, Guangdong Key Lab Liver Dis Res, Guangzhou, Guangdong, Peoples R China

来源：

TRANSPLANTATION PROCEEDINGS | 2018年 / 50卷 / 10期

基金：

中国国家自然科学基金;

关键词：

ENDOTHELIAL GROWTH-FACTOR; VEGF;

D O I：

10.1016/j.transproceed.2018.06.044

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Antiangiogenesis therapy plays an important role in the treatment of advanced hepatocellular carcinoma (HCC). However, treatment options for HCC recurrence after liver transplantation are currently limited. Apatinib is a small tyrosine kinase inhibitor molecule targeting vascular endothelial growth factor receptor-2. Here, we report for the first time one case of a patient with advanced HCC who received apatinib after occurring lung metastasis 7 months after liver transplantation. He took 500 mg of apatinib daily for one month, which was decreased to 250 mg daily because of side effects. The patient was confirmed to have a partial response, according to the Response Evaluation Criteria in Solid Tumors, for 10 months, and the progression-free survival time was greater than 21 months. Our data and experience have indicated that apatinib may be a good choice for HCC recurrence after liver transplantation.

引用

页码：4042 / 4045

页数：4

共 12 条

[1] The effect of stress on efficacy of dendritic cell therapy for esophageal squamous cell carcinoma [J].

Akutsu, Yasunori ;

Qin, Wei ;

Murakami, Kentaro ;

Hoshino, Isamu ;

Hanari, Naoyuki ;

Nishimori, Takanori ;

Mori, Mikito ;

Isozaki, Yuka ;

Toyozumi, Takeshi ;

Hu, Xin ;

Suito, Hiroshi ;

Akanuma, Naoki ;

Takahashi, Masahiko ;

Matsubara, Hisahiro .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)

[2] Cancer Statistics in China, 2015 [J].

Chen, Wanqing ;

Zheng, Rongshou ;

Baade, Peter D. ;

Zhang, Siwei ;

Zeng, Hongmei ;

Bray, Freddie ;

Jemal, Ahmedin ;

Yu, Xue Qin ;

He, Jie .

CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132

[3] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].

Cheng, Ann-Lii ;

Kang, Yoon-Koo ;

Chen, Zhendong ;

Tsao, Chao-Jung ;

Qin, Shukui ;

Kim, Jun Suk ;

Luo, Rongcheng ;

Feng, Jifeng ;

Ye, Shenglong ;

Yang, Tsai-Sheng ;

Xu, Jianming ;

Sun, Yan ;

Liang, Houjie ;

Liu, Jiwei ;

Wang, Jiejun ;

Tak, Won Young ;

Pan, Hongming ;

Burock, Karin ;

Zou, Jessie ;

Voliotis, Dimitris ;

Guan, Zhongzhen .

LANCET ONCOLOGY, 2009, 10 (01) :25-34

[4] CURRENT CONCEPTS Hepatocellular Carcinoma [J].

El-Serag, Hashem B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (12) :1118-1127

[5] Vascular endothelial growth factor as a target for anticancer therapy [J].

Ferrara, N .

ONCOLOGIST, 2004, 9 :2-10

[6] The biology of VEGF and its receptors [J].

Ferrara, N ;

Gerber, HP ;

LeCouter, J .

NATURE MEDICINE, 2003, 9 (06) :669-676

[7] Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction [J].

Li, Jin ;

Qin, Shukui ;

Xu, Jianming ;

Xiong, Jianping ;

Wu, Changping ;

Bai, Yuxian ;

Liu, Wei ;

Tong, Jiandong ;

Liu, Yunpeng ;

Xu, Ruihua ;

Wang, Zhehai ;

Wang, Qiong ;

Ouyang, Xuenong ;

Yang, Yan ;

Ba, Yi ;

Liang, Jun ;

Lin, Xiaoyan ;

Luo, Deyun ;

Zheng, Rongsheng ;

Wang, Xin ;

Sun, Guoping ;

Wang, Liwei ;

Zheng, Leizhen ;

Guo, Hong ;

Wu, Jingbo ;

Xu, Nong ;

Yang, Jianwei ;

Zhang, Honggang ;

Cheng, Ying ;

Wang, Ningju ;

Chen, Lei ;

Fan, Zhining ;

Sun, Piaoyang ;

Yu, Hao .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (13) :1448-+

[8] Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial [J].

Li, Jin ;

Qin, Shukui ;

Xu, Jianming ;

Guo, Weijian ;

Xiong, Jianping ;

Bai, Yuxian ;

Sun, Guoping ;

Yang, Yan ;

Wang, Liwei ;

Xu, Nong ;

Cheng, Ying ;

Wang, Zhehai ;

Zheng, Leizhen ;

Tao, Min ;

Zhu, Xiaodong ;

Ji, Dongmei ;

Liu, Xin ;

Yu, Hao .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3219-+

[9] Sorafenib in advanced hepatocellular carcinoma [J].

Llovet, Josep M. ;

Ricci, Sergio ;

Mazzaferro, Vincenzo ;

Hilgard, Philip ;

Gane, Edward ;

Blanc, Jean-Frederic ;

Cosme de Oliveira, Andre ;

Santoro, Armando ;

Raoul, Jean-Luc ;

Forner, Alejandro ;

Schwartz, Myron ;

Porta, Camillo ;

Zeuzem, Stefan ;

Bolondi, Luigi ;

Greten, Tim F. ;

Galle, Peter R. ;

Seitz, Jean-Francois ;

Borbath, Ivan ;

Haussinger, Dieter ;

Giannaris, Tom ;

Shan, Minghua ;

Moscovici, Marius ;

Voliotis, Dimitris ;

Bruix, Jordi .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :378-390

[10] Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma [J].

Peng, Hong ;

Zhang, Qiuyang ;

Li, Jiali ;

Zhang, Ning ;

Hua, Yunpeng ;

Xu, Lixia ;

Deng, Yubin ;

Lai, Jiaming ;

Peng, Zhenwei ;

Peng, Baogang ;

Chen, Minhu ;

Peng, Sui ;

Kuang, Ming .

ONCOTARGET, 2016, 7 (13) :17220-17229

← 1 2 →